A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.

@article{Emsley2005ARP,
  title={A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.},
  author={Hedley C A Emsley and Craig J Smith and Rachel F. Georgiou and Andy Vail and Stephen John Hopkins and Nancy J. Rothwell and Pippa Tyrrell},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={2005},
  volume={76 10},
  pages={1366-72}
}
OBJECTIVES The cytokine interleukin (IL)-1 mediates ischaemic brain damage in rodents. The endogenous, highly selective, IL-1 receptor antagonist (IL-1ra) protects against ischaemic cerebral injury in a range of experimental settings, and IL-1ra causes a marked reduction of cell death when administered peripherally or at a delay in transient cerebral ischaemia. We report here the first randomised, double blind, placebo controlled trial of recombinant human IL-1ra (rhIL-1ra) in patients with… CONTINUE READING
157 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 157 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

pathophysiology and neuroprotective clinical trial design

  • C Gong, JT Hoff, RF Keep
  • STROKE
  • 2002

Similar Papers

Loading similar papers…